DiaMedica Therapeutics Inc. Profile Avatar - Palmy Investing

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…

Biotechnology
US, Minneapolis [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of DMAC's Analysis
CIK: 1401040 CUSIP: 25253X207 ISIN: CA25253X2077 LEI: - UEI: -
Secondary Listings
DMAC has no secondary listings inside our databases.